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Introduction
Pompe disease, caused by the deficiency of acid alpha
glucosidase [GAA], ranges from the severe infantile to
attenuated adult forms. We present clinical features and
treatment outcomes from 4 paediatric cases from our
centre in the last 4 years.
Results
1) A 4-month-old female presented with hypotonia and
cardiomegaly. She was CRIM negative and homozygous
for p.R854X. She successfully received immunotolerance
induction therapy (ITI) prior to ERT at 4.5 months. She
remained antibody negative until 12 months, when titers
rose to 1:800. Hex4 increased from 48.4 at baseline to
108.8. LVMI decreased from 220 at baseline to 119 g/m2.
She started nocturnal BiPAP at 11 months, then devel-
oped pneumonia and became ventilator dependent, lead-
ing to cessation of ERT and death at 14 months.
2) A male infant born at 30-weeks was investigated for
hypertrophic cardiomyopathy and skeletal myopathy. He
was diagnosed at 4 months, was CRIM negative, and
homozygous for c 546+2 T>C . He received ITI, started
ERT at 4.1 months, and remains antibody negative.
Nocturnal BiPAP was started at 5 months. Hex4 dropped
from 59.7 at baseline to 54.9 at the last follow up. LVMI
decreased from 445 at baseline to 101.7 at 24 months. He
remains on ERT at 24 months and has achieved minor
motor gains.
3) A 6-month-old male infant presented with cardio-
myopathy and skeletal myopathy and was BiPAP depen-
dent. He was CRIM negative and had a c.2544delC /
complex deletion. The family elected not to pursue ERT
and he died at 7 months.
4) A 25-month-old male presented with recurrent
respiratory infections, proximal limb weakness, ventricular
hypertrophy and speech delay. He was CRIM positive and
heterozygous for p.P361L/p.R854X. He started ERT at
23 months. Hex4 dropped from 195.5 at baseline to 70.
Positive antibody titers of 1:200 at 2 months rose to 1:800
after 15 months. He remains on ERT after 18 months with
motor stability and has made developmental gains.
Discussion
The outcomes of our cases highlight the impact of ear-
lier diagnosis and treatment and the need for multidisci-
plinary support (particularly respiratory). Pre ERT ITI
was well tolerated.
Author details
1Division of Clinical & Metabolic Genetics, Hospital for Sick Children, Toronto,
Ontario, Canada. 2Division of Respiratory Medicine, Hospital for Sick Children,
Toronto, Ontario, Canada.
Published: 29 May 2013
doi:10.1186/1471-2474-14-S2-P3
Cite this article as: Raiman et al.: Spectrum of Pompe disease in
childhood – The Toronto experience. BMC Musculoskeletal Disorders 2013
14(Suppl 2):P3.
1Division of Clinical & Metabolic Genetics, Hospital for Sick Children, Toronto,
Ontario, Canada
Full list of author information is available at the end of the article
Raiman et al. BMC Musculoskeletal Disorders 2013, 14(Suppl 2):P3
http://www.biomedcentral.com/1471-2474/14/S2/P3
© 2013 Raiman et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
